JP Morgan Maintains Overweight on Anterix, Lowers Price Target to $130

Benzinga Newsdesk www.benzinga.com Negative 91.5%

Neg 91.5% Neu 0% Pos 0%

JP Morgan analyst Sebastiano Petti maintains Anterix (NASDAQ:ATEX) with a Overweight and lowers the price target from $133 to $130.